Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Date:3/1/2010

SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on February 26, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 24,000 shares of common stock to two new employees.

Both of the stock options are intended to be incentive stock options to the extent permitted by law and both have an exercise price per share equal to $6.28, the fair market value on the grant date. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee's continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

Both stock options were granted as an inducement material to the new employees' entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave®, has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: risks inherent in the continued analyses of clinical trial results, including Contrave Phase 3 trials; the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave and Empatic; reliance on third parties to assist with the development of Contrave and Empatic and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave or Empatic; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Orexigen Therapeutics, Inc.

Back to top

RELATED LINKS
http://www.Orexigen.com

'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
2. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
4. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
5. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... England , May 24, 2016 ... and Education in Clinical Neurophysiology  Elsevier ... information products and services, today announced the launch of ... an open access journal that focuses on clinical practice ... research, case reports, clinical series, normal values and didactic ...
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... LONDON , May 23, 2016 ... Surgical Devices, Diagnostics and Monitoring, and Vision Care ... Market? Which areas are going to grow at the ... potential revenues to 2026, assessing data, trends, opportunities and ... tables, charts, and graphs. Discover the most lucrative areas ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... , ... Boyd Industries, a leading supplier of dental chairs and cabinetry ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of ... Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
(Date:5/24/2016)... Bethpage, NY (PRWEB) , ... May 24, 2016 , ... ... of this growing trend, more gluten-free products are available and easily accessible. Whether someone ... they want to cater to a certain diet, King Kullen Grocery stocks their shelves ...
(Date:5/24/2016)... ROCKVILLE, Maryland (PRWEB) , ... May 24, 2016 ... ... today announced the appointment of Jonathan (Jon) Otterstatter to its board ... and is a proven leader in the development of technological innovations that lead ...
(Date:5/24/2016)... ... May 24, 2016 , ... Tuesday, May 24, Women's Excellence in ... enhanced with Young Living Essential Oils, taught by Patti Dolan, RYT, a Young ... location. Yoga Flow is 6:30pm - 7:15pm followed by a small intro to the ...
Breaking Medicine News(10 mins):